Journal article
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial
Abstract
The objective of this study was to evaluate the anxiolytic efficacy, and speed of onset of efficacy, of pregabalin (PGB) and venlafaxine-XR (VXR) in patients with generalized anxiety disorder (GAD). In this double-blind trial, outpatients, ages 18-65 years, who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, criteria for GAD were randomized to 8 weeks of flexible-dose treatment with PGB (300-600 mg/day), VXR (75-225 …
Authors
Kasper S; Herman B; Nivoli G; Van Ameringen M; Petralia A; Mandel FS; Baldinetti F; Bandelow B
Journal
International Clinical Psychopharmacology, Vol. 24, No. 2, pp. 87–96
Publisher
Wolters Kluwer
Publication Date
March 2009
DOI
10.1097/yic.0b013e32831d7980
ISSN
0268-1315
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAnti-Anxiety AgentsAnxiety DisordersCyclohexanolsDiagnostic and Statistical Manual of Mental DisordersDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansMaleMiddle AgedNeurotransmitter Uptake InhibitorsNorepinephrinePatient DropoutsPregabalinPsychiatric Status Rating ScalesQuality of LifeSelective Serotonin Reuptake InhibitorsTime FactorsVenlafaxine Hydrochloridegamma-Aminobutyric Acid